RxSight, Inc.RXSTEarnings & Financial Report
RxSight, Inc. is a medical technology company focused on developing and commercializing innovative intraocular lens solutions for patients undergoing cataract and refractive lens exchange procedures. Its flagship Light Adjustable Lens allows post-surgery power adjustment via a dedicated light delivery device, serving global ophthalmology care markets to improve post-operative visual outcomes for patients.
RXST Q4 FY2025 Key Financial Metrics
Revenue
$32.6M
Gross Profit
$25.3M
Operating Profit
$-11.3M
Net Profit
$-9.2M
Gross Margin
77.5%
Operating Margin
-34.8%
Net Margin
-28.1%
YoY Growth
-18.9%
EPS
$-0.22
RxSight, Inc. Q4 FY2025 Financial Summary
RxSight, Inc. reported revenue of $32.6M (down 18.9% YoY) for Q4 FY2025, with a net profit of $-9.2M (down 54.1% YoY) (-28.1% margin). Cost of goods sold was $7.3M, operating expenses totaled $36.6M.
Key Financial Metrics
| Total Revenue | $32.6M |
|---|---|
| Net Profit | $-9.2M |
| Gross Margin | 77.5% |
| Operating Margin | -34.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
RxSight, Inc. Q4 FY2025 revenue of $32.6M breaks down across 3 segments, led by Rxlal at $28.2M (86.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Rxlal | $28.2M | 86.4% |
| LDD | $3.0M | 9.1% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4.5% |
RxSight, Inc. Revenue by Segment — Quarterly Trend
RxSight, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Rxlal and LDD) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Rxlal | $28.2M | $25.7M | $27.0M | $27.2M |
| LDD | $3.0M | $3.2M | $5.1M | $9.4M |
| Service Warranty Service Contracts And Accessories | $1.5M | $1.5M | $1.5M | $1.3M |
RxSight, Inc. Annual Revenue by Year
RxSight, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $134.5M).
RxSight, Inc. Quarterly Revenue & Net Profit History
RxSight, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $32.6M | -18.9% | $-9.2M | -28.1% |
| Q3 FY2025 | $30.3M | -14.1% | $-9.8M | -32.4% |
| Q2 FY2025 | $33.6M | -3.6% | $-11.8M | -35.0% |
| Q1 FY2025 | $37.9M | +28.4% | $-8.2M | -21.6% |
| Q4 FY2024 | $40.2M | +40.7% | $-5.9M | -14.8% |
| Q3 FY2024 | $35.3M | +59.1% | $-6.3M | -17.9% |
| Q2 FY2024 | $34.9M | +67.6% | $-6.1M | -17.4% |
| Q1 FY2024 | $29.5M | +68.7% | $-9.1M | -30.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.5M | $34.9M | $35.3M | $40.2M | $37.9M | $33.6M | $30.3M | $32.6M |
| YoY Growth | 68.7% | 67.6% | 59.1% | 40.7% | 28.4% | -3.6% | -14.1% | -18.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $183.2M | $305.5M | $310.5M | $318.6M | $313.0M | $309.0M | $308.5M | $311.8M |
| Liabilities | $19.2M | $30.3M | $33.2M | $37.3M | $33.7M | $31.0M | $32.6M | $36.1M |
| Equity | $163.9M | $275.2M | $277.3M | $281.2M | $279.3M | $278.0M | $276.0M | $275.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.3M | $-4.0M | $650000 | $-4.3M | $-8.8M | $-4.4M | $-1.2M | $-1.1M |